Edwards Lifesciences (EW)

NYSEHealth CareMedical - DevicesSnapshot 2026-10-15

$86.60-1.70%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Edwards Lifesciences’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.1%

+10% or more+5%0%−5%−10% or less

3.39 → 3.39 EPS · FY ending Dec 31, 2027 · 16 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 16 to 16; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

Three key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Adjusted EPS reaches at least $2.95 in FY 2026	A primary condition in Edwards Lifesciences's published investment case. The stated target is >= $2.95.	Intact	EPS falls below $2.95 in FY 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Total revenue grows to at least $6.5 billion in FY 2026	A primary condition in Edwards Lifesciences's published investment case. The stated target is >= $6.5 billion.	Intact	Revenue falls below $6.5 billion in FY 2026	Revenue: $1.741B FY2026-Q2; GAAP. Published target: >= $6.5 billion. Target period is not explicitly aligned with this observation. Source published Aug 4, 20261,741,000,000 USD · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 15c8500f-c5a3-4723-a949-1e89da8cdaf5. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
TAVR sales grow at least 7% in FY 2026, reaching $1.2 billion in Q1	TAVR sales expand steadily, reaching $1.2 billion in Q1 2026.	Intact	TAVR sales growth falls below 7% in FY 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 7 of last 7 quarters. TAVR sales grew from $1.05 billion in 2025-Q1 to $1.26 billion in 2026-Q2, with management raising constant currency sales growth guidance from 6%-7% in 2025-Q2 to 8%-9% in 2026-Q2. The trajectory shows delivering growth aligned with stated priorities. Delivery assessment Oct 15, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$3.39

$3.38 → $3.39 · observed estimates

FY2027 revenue$7.42B

$7.43B → $7.42B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$3.38	$7,430,097,595	16 / 21
2026-07-25	$3.37	$7,423,681,080	27 / 27
2026-07-26	$3.37	$7,423,681,080	27 / 27
2026-07-27	$3.37	$7,422,777,380	27 / 27
2026-07-28	$3.38	$7,435,572,660	16 / 21
2026-07-29	$3.38	$7,435,572,660	16 / 21
2026-07-30	$3.38	$7,414,786,800	16 / 22
2026-07-31	$3.38	$7,414,786,800	16 / 22
2026-08-01	$3.38	$7,414,786,800	16 / 22
2026-08-02	$3.38	$7,429,110,230	28 / 28
2026-08-03	$3.38	$7,429,113,950	28 / 28
2026-08-04	$3.38	$7,417,342,355	16 / 22
2026-08-05	$3.38	$7,429,113,950	28 / 28
2026-08-06	$3.38	$7,417,342,355	16 / 22
2026-08-07	$3.38	$7,417,342,355	16 / 22
2026-08-08	$3.38	$7,429,113,950	28 / 28
2026-08-09	$3.38	$7,429,113,950	28 / 28
2026-08-10	$3.38	$7,429,113,950	28 / 28
2026-08-11	$3.38	$7,417,342,355	16 / 22
2026-08-12	$3.38	$7,417,342,355	16 / 22
2026-08-13	$3.38	$7,429,113,950	28 / 28
2026-08-14	$3.38	$7,417,342,355	16 / 22
2026-08-15	$3.38	$7,417,342,355	16 / 22
2026-08-16	$3.38	$7,417,342,355	16 / 22
2026-08-17	$3.38	$7,417,342,355	16 / 22
2026-08-18	$3.38	$7,417,342,355	16 / 22
2026-08-19	$3.38	$7,417,342,355	16 / 22
2026-08-20	$3.38	$7,418,548,511	16 / 22
2026-08-21	$3.38	$7,418,548,511	16 / 22
2026-08-22	$3.38	$7,418,548,511	16 / 22
2026-08-23	$3.39	$7,418,548,511	16 / 22
2026-08-24	$3.39	$7,418,548,511	16 / 22
2026-08-25	$3.39	$7,418,548,511	16 / 22
2026-08-26	$3.39	$7,418,548,511	16 / 22
2026-08-27	$3.39	$7,418,548,511	16 / 22
2026-08-28	$3.39	$7,418,548,511	16 / 22
2026-08-29	$3.39	$7,418,548,511	16 / 22
2026-08-30	$3.39	$7,418,565,950	16 / 22
2026-08-31	$3.39	$7,418,565,950	16 / 22
2026-09-01	$3.39	$7,418,565,950	16 / 22
2026-09-02	$3.39	$7,418,735,173	16 / 22
2026-09-03	$3.39	$7,418,735,173	16 / 22
2026-09-04	$3.39	$7,418,735,173	16 / 22
2026-09-05	$3.39	$7,418,735,173	16 / 22
2026-09-06	$3.39	$7,418,735,173	16 / 22
2026-09-07	$3.39	$7,418,735,173	16 / 22
2026-09-08	$3.39	$7,418,735,173	16 / 22
2026-09-09	$3.39	$7,418,735,173	16 / 22
2026-09-10	$3.39	$7,418,735,173	16 / 22
2026-09-11	$3.38	$7,418,719,788	16 / 22
2026-09-12	$3.39	$7,418,412,096	16 / 22
2026-09-13	$3.39	$7,418,412,096	16 / 22
2026-09-14	$3.39	$7,418,412,096	16 / 22
2026-09-15	$3.39	$7,418,412,096	16 / 22
2026-09-16	$3.39	$7,418,412,096	16 / 22
2026-09-17	$3.39	$7,418,412,096	16 / 22
2026-09-18	$3.39	$7,418,412,096	16 / 22
2026-09-19	$3.39	$7,418,412,096	16 / 22
2026-09-20	$3.39	$7,418,412,096	16 / 22
2026-09-21	$3.39	$7,418,412,096	16 / 22
2026-09-22	$3.39	$7,418,412,096	16 / 22
2026-09-23	$3.39	$7,418,412,096	16 / 22
2026-09-24	$3.39	$7,418,412,096	16 / 22
2026-09-25	$3.39	$7,418,412,096	16 / 22
2026-09-26	$3.39	$7,418,412,096	16 / 22
2026-09-27	$3.39	$7,418,412,096	16 / 22
2026-09-28	$3.39	$7,418,412,096	16 / 22
2026-09-29	$3.39	$7,418,412,096	16 / 22
2026-09-30	$3.39	$7,418,412,096	16 / 22
2026-10-01	$3.39	$7,418,719,788	16 / 22
2026-10-02	$3.39	$7,418,723,634	16 / 22
2026-10-03	$3.39	$7,418,723,634	16 / 22
2026-10-04	$3.39	$7,418,723,634	16 / 22
2026-10-05	$3.39	$7,418,723,634	16 / 22
2026-10-06	$3.39	$7,420,108,250	16 / 22
2026-10-07	$3.39	$7,420,108,250	16 / 21
2026-10-08	$3.39	$7,420,108,250	16 / 21
2026-10-09	$3.39	$7,420,108,250	16 / 21
2026-10-10	$3.39	$7,420,108,250	16 / 21
2026-10-11	$3.39	$7,420,108,250	16 / 21
2026-10-12	$3.39	$7,420,108,250	16 / 21
2026-10-13	$3.39	$7,420,112,996	16 / 21
2026-10-14	$3.39	$7,420,121,204	16 / 21
2026-10-15	$3.39	$7,420,121,204	16 / 21

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	22	8
2026-06-01	21	8
2026-07-01	22	8
2026-08-01	22	7
2026-09-01	22	7
2026-10-01	23	7

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 23 Buy / Strong Buy · 7 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 16–Oct 15 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Adjusted EPS reaches at least $2.95 in FY 2026Direct metric needs a verified mapping
Total revenue grows to at least $6.5 billion in FY 2026Revenue: $1.741B
TAVR sales grow at least 7% in FY 2026, reaching $1.2 billion in Q1Direct metric needs a verified mapping

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

0.9%Typical daily move · historical

Downside history

-13.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Edwards Lifesciences outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This is a durable compounder with a focus on consistent sales growth. The current thesis state is intact, supported by strong recent financial performance and management's commitment to growth targets.

What's priced into Edwards Lifesciences

The market appears to have priced in a premium compared to peers, reflecting a justified valuation despite the current expensive nature. There is a slight expectations gap, indicating that the market may not fully anticipate future performance.

What the fundamentals likely do

Fundamentals are likely to remain stable, driven by management's execution on growth priorities. Recent results show strong sales growth in key areas, although there is a moderate risk of missing expectations given industry trends.

What Edwards Lifesciences hinges on

The long-term thesis hinges on maintaining credibility with guidance and the performance of sector bellwethers. Additionally, broader economic conditions, such as employment trends, could impact the company's performance.